The FDA announced accelerated review for three companies studying psilocybin and methylone as treatments for depression and PTSD.
President Trump signed an executive order directing faster development and approval of psychedelic therapies.
The agency approved a Phase 1 clinical trial of noribogaine hydrochloride for alcohol use disorder treatment.
HHS Secretary Robert F. Kennedy Jr. cited the veteran suicide crisis as a driving force behind the initiative.
A systematic review of psilocybin studies found significant reduction in depressive symptoms with fewer side effects than SSRIs.
Psychedelic Research Gets Government Green Light
Read Full Article: https://www.naturalnews.com/2026-04-27-fda-fast-tracks-psychedelic-drugs-for-depression-and-ptsd-treatment.html
